Loading organizations...
Allink Biotherapeutics is a clinical-stage biotechnology company developing next-generation bispecific antibodies and antibody-drug conjugate therapeutics, based in the Pudong New Area of Shanghai, China. The enterprise leverages proprietary platforms to create advanced biologic treatments targeting unmet medical needs across the oncology and immunology sectors globally. Operating with a portfolio of over 10 innovative drug pipelines and more than 5 patents, the firm has rapidly advanced its lead asset and two additional candidates into the clinical stage. In November 2024, the business successfully secured $42 million in Series A financing to further its clinical research and development efforts. This recent funding round was led by Lanchi Ventures, with additional participation from prominent institutional investors including Yuanbio Venture Capital, Legend Capital, Med-Fine Capital, and Gaorong Ventures. Allink Biotherapeutics was founded in 2023 by Hui Feng and Kehua Fan.
Allink Biotherapeutics has raised $89.0M across 2 funding rounds.
Allink Biotherapeutics has raised $89.0M in total across 2 funding rounds.
Allink Biotherapeutics has raised $89.0M in total across 2 funding rounds.
Allink Biotherapeutics's investors include 郭学婧, Tan Hong, 5Y Capital, Lapam Capital, Jiangtao Yu, Legend Capital, Vince Deng.
Allink Biotherapeutics has raised $89.0M across 2 funding rounds. Most recently, it raised $47.0M Series A Extension in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2025 | $47M Series A Plus | 郭学婧, TAN Hong | 5Y Capital, Lapam Capital | Announced |
| Nov 28, 2024 | $42M Series A | — | Jiangtao YU, Legend Capital, Vince Deng | Announced |
